Enhanced normal tissue doses caused by tumour shrinkage during brachytherapy.
Published data concerning shrinkage rates of low-grade gliomas implanted with 125I seeds have been used to determine the likely influence of such shrinkage on normal tissue doses. It is demonstrated that a tumour volume shrinkage of 50% over 6 months can bring about a 30% increase in the dose delivered to tissues which shrink centripetally towards the implanted volume. The use of radionuclides with a half-life shorter than that of 125I would substantially reduce shrinkage-induced dose increments.
Dale
R G
RG
Hammersmith Hospitals NHS Trust, Charing Cross Hospital, London, UK.
Jones
B
B
D001918:Brachytherapy / Q000009:adverse effects*; D005910:Glioma / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage; D011829:Radiation Dosage
D007457:Iodine Radioisotopes